Business

Biotech, pharma, and money in science

Apple - top 5
Business

5 names to know at Apple: the people leading its move into health care

By Rebecca Robbins

Scale
Biotech

Gelesis aims to crack the weight-loss market with its new capsule

By Jonathan Saltzman — Boston Globe

Biotech

With real estate deal, Sanofi Genzyme boosts its bottom line in hot market

By Tim Logan

Elizabeth Holmes Theranos
Business

Ex-Theranos CEO Elizabeth Holmes to return to court in July to set possible trial date

By Rebecca Robbins and Damian Garde

Biotech

How does Biogen move beyond its Alzheimer’s drug blowup? Listen for the clues

By Adam Feuerstein

Biotech

A biotech startup’s lofty goal: Kill cancer with pills that target RNA instead of proteins

By Adam Feuerstein

IBM logo
Exclusive

IBM halting sales of Watson AI tool for drug discovery amid sluggish growth

By Casey Ross

Pharmalot

Pharmalittle: Stronger warnings urged for Amgen’s osteoporosis drug; prices in drug ads can be jarring

By Ed Silverman and Elizabeth Cooney

Amazon logo - photo illo
Business

5 names to know at Amazon: the key players behind its health care push

By Casey Ross

Liver illustration
Biotech

The NASH race: A fleeting frontrunner, a stumbling giant, and others in biotech look to the finish line

By Adam Feuerstein

Dr. Peter Bach
Business

Peter Bach’s latest crazy idea: Give up on biosimilars. Regulate drug prices instead

By Matthew Herper and Ed Silverman

JUST MERGERED
Pharma

The Bristol-Celgene merger is approved. Here are 8 challenges ahead

By Damian Garde and Adam Feuerstein

Biotech

Gilead Sciences to lay off one-fifth of sales force as financial pressures build

By Adam Feuerstein

headquarters of Verily Life Sciences
Business

5 names to know at Verily: Players to watch at Alphabet’s life sciences unit

By Rebecca Robbins

Medicare Scam
Health

Feds break up $1.2 billion Medicare orthopedic brace scam

By Associated Press

Pharmalot

Pharmalittle: House Republicans warn pharma over Democrats’ pricing probe; Glaxo wins FDA nod for HIV pill

By Ed Silverman

Pharmaceutical company Takeda
Pharmalot

European Union files complaint against Turkey for ‘discriminating’ against foreign drug makers

By Ed Silverman

Duchenne muscular dystrophy Histopathology
Biotech

Audentes Therapeutics to develop gene therapies for two types of muscular dystrophy, including Duchenne

By Matthew Herper

Lot of white capsules on a blue background.
Biotech

6 things to know before the readout of BioCryst Pharma’s pivotal clinical trial

By Adam Feuerstein

John Kapoor
Pharma

At opioid racketeering trial, defense puts blame on government’s star witness

By Jonathan Saltzman — Boston Globe

iCarbonX offices
Business

U.S. forces health company to ditch Chinese investor, in sign of heightened concern over foreign influence

By Rebecca Robbins, Matthew Herper, and Damian Garde

Scorecard
Biotech

The biotech scorecard for the second quarter: 18 stock-moving events to watch

By Adam Feuerstein

Patrick Soon-Shiong
Pharmalot

A small drug maker accuses Soon-Shiong of masterminding a ‘catch-and-kill’ scheme

By Ed Silverman

Insulin factory - Novo
Health

Faced with rising anger on drug prices, Cigna plans to reduce insulin costs to $25 a month for many patients

By Matthew Herper

Novartis International pharmaceutical
Pharmalot

After years of delay, Novartis faces an upcoming trial for allegedly paying kickbacks to doctors

By Ed Silverman

Cyclerion
Biotech

Maturing Ironwood is spinning off Cyclerion, its edgy, risk-taking kid brother

By Jonathan Saltzman — Boston Globe

Business

Novartis acquires Boston-based IFM Tre for work on drugs to modify the immune system

By Kate Sheridan

CRISPR Panel March 28 2019
Biotech

CRISPR companies embrace the hope — and pressure — of a rapidly advancing technology

By Damian Garde

Microbiome illo
Biotech

Microbiome companies look beyond the gut for new therapies

By Kate Sheridan

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy